PT  - JOURNAL ARTICLE
AU  - MIYAHARA, DAISUKE
AU  - KATSUTA, TAKAHIRO
AU  - MAEHARA, MIYAKO
AU  - TAKAHASHI, YOKO
AU  - FUKAGAWA, SATOSHI
AU  - MIYATA, KOUHEI
AU  - KIYOSHIMA, CHIHIRO
AU  - YOTSUMOTO, FUSANORI
AU  - ANAN, HARUCHIKA
AU  - MIYAMOTO, SHINGO
TI  - Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer
DP  - 2016 Jul 01
TA  - Anticancer Research
PG  - 3725--3729
VI  - 36
IP  - 7
4099  - http://ar.iiarjournals.org/content/36/7/3725.short
4100  - http://ar.iiarjournals.org/content/36/7/3725.full
SO  - Anticancer Res2016 Jul 01; 36
AB  - Background: Endometrial cancer (EC) has a poor prognosis due to drug resistance. Patients and Methods: We evaluated the safety and efficacy of adjuvant combination chemotherapy with docetaxel plus cisplatin ((DP) docetaxel, 70 mg/m2; cisplatin, 60 mg/m2; every 28 days) in EC patients at intermediate-risk (IR) or high-risk (HR) for recurrence. Results: Sixty-four patients diagnosed with EC were enrolled. Stage-I, -II, -III and -IV disease was noted in 23, 7, 28 and 6 patients, respectively. Histopathological analyses revealed that 56, 3, 1 and 4 patients had endometrioid, serous, clear-cell or “other” types of carcinoma. Grade-3/4 hematologic toxicities were found at 80% and 95% in patients in IR and HR groups, respectively. In IR and HR groups, mean progression-free (PFS) survival was 69.5 and 29.5, while overall survival (OS) was 59.6 and 47.5 months, respectively. Conclusion: DP may be clinically safe and useful treatment for EC.